Pfizer (NYSE:PFE) Stock Price Up 2.4% – Here’s Why

Pfizer Inc. (NYSE:PFE) rose 2.4% during mid-day trading on Tuesday . The company traded as high as $26.83 and last traded at $26.49. Approximately 74,198,402 shares were traded during trading, an increase of 49% from the average daily volume of 49,889,852 shares. The stock had previously closed at $25.88.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target on PFE to $27 (from $24), providing an immediate bullish catalyst for the stock. Why Is Pfizer Stock Rising Tuesday?
• Positive Sentiment: A Seeking Alpha author reiterates a bullish stance on Pfizer, arguing strategic plans and portfolio strength support upside despite near-term headwinds. Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance
• Neutral Sentiment: Summary of current Wall Street analyst target prices for Pfizer — useful context for where the market expects shares to trade but not a direct catalyst on its own. What are Wall Street analysts’ target price for Pfizer stock?
• Neutral Sentiment: Analyst insight roundup on healthcare companies including Pfizer — background on market positioning and analyst views. Analysts Offer Insights on Healthcare Companies: Pfizer (PFE)
• Neutral Sentiment: Profile/interview piece on CEO Albert Bourla — useful for long-term governance and strategy color but unlikely to move share price materially in the near term. Pfizer’s CEO on leading after a moonshot—and making deals with Trump
• Negative Sentiment: Zacks warns Q4 earnings are expected to decline, signaling risk of an earnings miss or weaker guidance that could pressure the stock around the report. Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline
• Negative Sentiment: Aclaris reported a hair-loss candidate that outperformed Pfizer’s Litfulo in preclinical results — a competitive risk for a key dermatology asset. Aclaris Hair Loss Drug Shows Faster Results Than Pfizer’s Drug
• Negative Sentiment: Analysis flags Pfizer’s use of debt across multiple measures, which could raise investor concern about balance-sheet flexibility if growth slows. These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively
• Negative Sentiment: Forbes notes Pfizer’s underperformance vs. peers due to fading COVID demand and an upcoming patent cliff — structural headwinds that could limit upside. Pfizer vs. Merck Stock And JNJ

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. UBS Group initiated coverage on shares of Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price for the company. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Citigroup assumed coverage on shares of Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target on the stock. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price target on shares of Pfizer in a research report on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $28.06.

Pfizer Stock Up 2.4%

The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The business’s 50 day moving average is $25.41 and its 200-day moving average is $25.00. The firm has a market capitalization of $150.61 billion, a price-to-earnings ratio of 15.40 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The firm had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. Pfizer’s payout ratio is presently 100.00%.

Hedge Funds Weigh In On Pfizer

Several large investors have recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its position in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares in the last quarter. Patton Fund Management Inc. acquired a new position in shares of Pfizer in the 2nd quarter worth approximately $233,000. ORG Partners LLC grew its position in Pfizer by 17.3% during the 2nd quarter. ORG Partners LLC now owns 4,013 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 593 shares during the last quarter. Finally, Tempus Wealth Planning LLC increased its holdings in Pfizer by 5.2% during the 2nd quarter. Tempus Wealth Planning LLC now owns 25,918 shares of the biopharmaceutical company’s stock valued at $628,000 after purchasing an additional 1,284 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.